Recent advances in proteomics and cancer biomarker discovery

Gary Guishan Xiao, Robert R. Recker, Hong Wen Deng

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status can also serve as powerful tools in monitoring the course of cancer and in determining the efficacy and safety of novel therapies. Thus, discovery of novel specific biomarkers are needed that may provide informative clues for early diagnosis and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. The progress that has been made in this field is helpful in identifying biomarkers that can be used for early diagnosis of cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the current state of the art in this field.

Original languageEnglish
Pages (from-to)63-72
Number of pages10
JournalClinical Medicine: Oncology
Volume2
StatePublished - Feb 9 2008

Fingerprint

Tumor Biomarkers
Proteomics
Early Detection of Cancer
Early Diagnosis
Neoplasms
Biomarkers
Technology
Morbidity
Safety
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Recent advances in proteomics and cancer biomarker discovery. / Xiao, Gary Guishan; Recker, Robert R.; Deng, Hong Wen.

In: Clinical Medicine: Oncology, Vol. 2, 09.02.2008, p. 63-72.

Research output: Contribution to journalReview article

Xiao, Gary Guishan ; Recker, Robert R. ; Deng, Hong Wen. / Recent advances in proteomics and cancer biomarker discovery. In: Clinical Medicine: Oncology. 2008 ; Vol. 2. pp. 63-72.
@article{49665c630e6944e991d10458384da3b5,
title = "Recent advances in proteomics and cancer biomarker discovery",
abstract = "Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status can also serve as powerful tools in monitoring the course of cancer and in determining the efficacy and safety of novel therapies. Thus, discovery of novel specific biomarkers are needed that may provide informative clues for early diagnosis and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. The progress that has been made in this field is helpful in identifying biomarkers that can be used for early diagnosis of cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the current state of the art in this field.",
author = "Xiao, {Gary Guishan} and Recker, {Robert R.} and Deng, {Hong Wen}",
year = "2008",
month = "2",
day = "9",
language = "English",
volume = "2",
pages = "63--72",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Recent advances in proteomics and cancer biomarker discovery

AU - Xiao, Gary Guishan

AU - Recker, Robert R.

AU - Deng, Hong Wen

PY - 2008/2/9

Y1 - 2008/2/9

N2 - Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status can also serve as powerful tools in monitoring the course of cancer and in determining the efficacy and safety of novel therapies. Thus, discovery of novel specific biomarkers are needed that may provide informative clues for early diagnosis and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. The progress that has been made in this field is helpful in identifying biomarkers that can be used for early diagnosis of cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the current state of the art in this field.

AB - Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status can also serve as powerful tools in monitoring the course of cancer and in determining the efficacy and safety of novel therapies. Thus, discovery of novel specific biomarkers are needed that may provide informative clues for early diagnosis and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. The progress that has been made in this field is helpful in identifying biomarkers that can be used for early diagnosis of cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the current state of the art in this field.

UR - http://www.scopus.com/inward/record.url?scp=84911892144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911892144&partnerID=8YFLogxK

M3 - Review article

VL - 2

SP - 63

EP - 72

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -